New treatment offers fresh hope to cystic fibrosis patients

• The National Institute for Health and Care Excellence (Nice) has approved Alyftrek, a new modulator therapy for cystic fibrosis, hailed as "life-changing" by health experts.
• NHS England will make Alyftrek available to hundreds of patients aged six and over, including those with the rarest forms of the condition who previously had no access to such treatments.
• The new pill, also known as vanza triple, works by tackling the underlying cause of cystic fibrosis, a genetic condition affecting the lungs and digestive system.
• This approval means that 95 per cent of people with cystic fibrosis in England will now be eligible for modulator therapy.
• The treatment is said to offer fresh hope, can transform life expectancy and quality of life, and reduce the burden of hospital appointments for patients.

IN FULL

‘Life-changing’ therapy now available for cystic fibrosis patients